JUXTAPID
Total Payments
$19.8M
Transactions
2,779
Doctors
1,747
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.8M | 237 | 167 |
| 2021 | $2.1M | 782 | 650 |
| 2020 | $2.3M | 237 | 116 |
| 2019 | $7.7M | 377 | 330 |
| 2018 | $2.7M | 439 | 345 |
| 2017 | $3.2M | 707 | 562 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $19.5M | 27 | 98.3% |
| Unspecified | $156,093 | 266 | 0.8% |
| Consulting Fee | $54,500 | 15 | 0.3% |
| Food and Beverage | $41,104 | 2,364 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $32,713 | 43 | 0.2% |
| Honoraria | $32,340 | 19 | 0.2% |
| Travel and Lodging | $9,612 | 40 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $6,000 | 3 | 0.0% |
| Grant | $508.00 | 1 | 0.0% |
| Education | $10.00 | 1 | 0.0% |
Payments by Type
General
$19.6M
2,513 transactions
Research
$156,093
266 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| LOWER: Lomitapide Observational Worldwide Evaluation Registry | Amryt Pharma Holdings Ltd | $104,260 | 8 |
| LOWER:LomitapideObservational Worldwide Evaluation Registry (LOWER) | Chiesi USA, Inc. | $28,166 | 7 |
| Aegerion Lomitapide ClinDevOps | Aegerion Pharmaceuticals, Inc. | $23,667 | 6 |
Top Doctors Receiving Payments for JUXTAPID — Page 70
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Interventional Cardiology | Mishawaka, IN | $11.00 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Springfield, MO | $10.97 | 1 |
| , M.D | Family Medicine | Springfield, MO | $10.97 | 1 |
| , MD | Internal Medicine | Springfield, MO | $10.97 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Idaho Falls, ID | $10.95 | 1 |
| Harry D Agostino | — | Jacksonville, FL | $10.94 | 1 |
| , MD | Internal Medicine | Akron, OH | $10.93 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Morristown, TN | $10.89 | 1 |
| , MD | Internal Medicine | Chardon, OH | $10.87 | 1 |
| , M.D | Family Medicine | Gonzales, LA | $10.82 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Scottsdale, AZ | $10.70 | 1 |
| , DO | Internal Medicine | Fort Myers, FL | $10.68 | 1 |
| Sheri Baczkowski | — | Buffalo, NY | $10.67 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | New Albany, IN | $10.66 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Louisville, KY | $10.66 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Indianapolis, IN | $10.63 | 1 |
| , MD | Internal Medicine | Lincoln, NE | $10.61 | 1 |
| , M.D | Cardiovascular Disease | Lincoln, NE | $10.61 | 1 |
| , MD | Family Medicine | Colorado Springs, CO | $10.58 | 1 |
| , MD | Internal Medicine | Willoughby, OH | $10.57 | 1 |
| , MD | Cardiovascular Disease | Sellersville, PA | $10.49 | 1 |
| , M.D | Nuclear Medicine | Blue Ash, OH | $10.44 | 1 |
| , M.D | Cardiovascular Disease | Overland Park, KS | $10.38 | 1 |
Ad
Manufacturing Companies
- Aegerion Pharmaceuticals, Inc. $13.6M
- Amryt Pharma Holdings Ltd $4.4M
- Chiesi USA, Inc. $1.8M
Product Information
- Type Drug
- Total Payments $19.8M
- Total Doctors 1,747
- Transactions 2,779
About JUXTAPID
JUXTAPID is a drug associated with $19.8M in payments to 1,747 healthcare providers, recorded across 2,779 transactions in the CMS Open Payments database. The primary manufacturer is Aegerion Pharmaceuticals, Inc..
Payment data is available from 2017 to 2024. In 2024, $1.8M was paid across 237 transactions to 167 doctors.
The most common payment nature for JUXTAPID is "Royalty or License" ($19.5M, 98.3% of total).
JUXTAPID is associated with 3 research studies, including "LOWER: Lomitapide Observational Worldwide Evaluation Registry" ($104,260).